U.S. Chemicals Stock News

NYSE:BVN
NYSE:BVNMetals and Mining

Buenaventura Permits And San Gabriel Ramp Up Reframe Earnings Outlook

Compañía de Minas BuenaventuraA (NYSE:BVN) reported multiple operational and permitting milestones in Q1 2026, including the production ramp up at San Gabriel. The company received key stage 1 operating and water use permits for San Gabriel, while Yumpag and El Brocal secured capacity expansion approvals. Gold production, company wide revenue, and profitability all saw significant gains in the quarter, alongside these project advances. For investors watching NYSE:BVN, these updates come...
NasdaqCM:GRRR
NasdaqCM:GRRRSoftware

Gorilla Technology Group (GRRR) Is Up 17.9% After $2.8 Billion India AI Infrastructure Expansion

In recent days, Gorilla Technology Group Inc. announced a significant expansion of its India AI infrastructure collaboration with Yotta Data Services, supporting the deployment of 20,736 additional B300 GPU cards in a multi-year project valued at about US$2.80 billion, alongside a deeper investment in real-time infrastructure intelligence firm Astrikos.AI. This combination of a very large GPU deployment tied to one of APAC’s largest NVIDIA DGX Cloud clusters and closer Astrikos.AI...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Is It Too Late To Consider Travere Therapeutics (TVTX) After Its Strong Share Price Rally?

Wondering whether Travere Therapeutics at around US$44.12 is still offering value or if the easy gains are already behind it? This article unpacks what the current price really implies. The stock has shown strong share price moves, with returns of 8.9% over 7 days, 40.4% over 30 days, 11.6% year to date, 108.6% over 1 year, 162.6% over 3 years and 120.5% over 5 years. This naturally raises questions about both upside potential and risk. Recent headlines around Travere Therapeutics have...
NYSE:LOW
NYSE:LOWSpecialty Retail

Lowe's Pro Card Expansion Aims To Deepen Contractor Spend And Insights

Synchrony and Lowe's Companies have expanded their partnership with the launch of the MyLowe's Pro Rewards American Express Card. The new co branded card extends purchasing power and rewards for professional customers beyond Lowe's stores to any location where American Express is accepted. The offering targets small to medium business customers within Lowe's Pro segment, with a focus on broader rewards and financing flexibility. Lowe's Companies, NYSE:LOW, is trading at $233.33, with the...
NYSE:BMY
NYSE:BMYPharmaceuticals

Bristol Myers Squibb (BMY) Margin Strength In Q1 2026 Challenges Bearish Earnings Narratives

Bristol-Myers Squibb (BMY) opened 2026 with Q1 revenue of US$11.5b, basic EPS of US$1.31 and net income of US$2.7b, setting the tone for how investors will judge its recent profitability. The company has seen quarterly revenue move from US$11.2b and basic EPS of US$1.21 in Q1 2025 to US$11.5b and US$1.31 in Q1 2026. Trailing twelve month EPS reached US$3.57, giving a clearer read on earnings power over the last year. With trailing net profit margin at 15% and recent earnings growth of 34.2%...
NYSE:EMN
NYSE:EMNChemicals

Eastman Chemical Q1 2026 Margin Compression Tests Bullish Earnings Growth Narrative

Eastman Chemical Q1 2026 earnings: headline numbers in focus Eastman Chemical (EMN) has opened 2026 with Q1 revenue of US$2.2b and basic EPS of US$0.94, setting the stage for how investors assess the latest move in profitability. Over recent quarters the company has seen revenue move between US$2.0b and US$2.3b, with basic EPS ranging from US$0.41 to US$2.85, while trailing twelve month EPS sits at US$3.49 on revenue of US$8.6b. With the stock at US$77.53 and trailing net margin at 4.6%...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

T. Rowe Price Group (TROW) Margin Stability Reinforces Income Narrative Despite Q1 AUM Outflows

T. Rowe Price Group (TROW) opened 2026 with Q1 revenue of US$1.9 billion and basic EPS of US$2.23, alongside trailing twelve month revenue of US$7.4 billion and EPS of US$9.34 that sit against modest 1.9% annual revenue growth and a 27.6% net profit margin over the past year. Over recent quarters, revenue has ranged from US$1.7 billion to US$1.9 billion, while quarterly EPS has moved between roughly US$1.93 and US$2.88. This provides a consistent picture of earnings power, even as the five...
NYSE:DRI
NYSE:DRIHospitality

Smokey Bones Closure Puts Darden Restaurants Valuation And Brand Decisions In Focus

Smokey Bones, the barbecue chain originally founded by Darden Restaurants, has been fully closed after a 27 year run. The shutdown ends a long standing brand legacy that traces back to Darden’s earlier expansion in American casual dining. Although Darden no longer owns Smokey Bones, the closure adds context for investors tracking NYSE:DRI and the broader barbecue and casual dining space. Darden Restaurants, trading as NYSE:DRI, is coming off a mixed share performance backdrop, with the...
NYSE:KIM
NYSE:KIMRetail REITs

Is Kimco Realty (KIM) Offering Value After Mixed Multi Year Share Price Performance

If you are wondering whether Kimco Realty's current share price lines up with its underlying value, this article walks through the key numbers so you can judge that for yourself. Over recent periods the stock has seen mixed returns, with a 1.3% decline over the last 7 days, a 4.1% gain over 30 days, 16.6% year to date, 16.0% over 1 year, 43.7% over 3 years and 35.3% over 5 years. Recent coverage of Kimco Realty has focused on its role as a large retail REIT and how investors are weighing...
NasdaqGS:NBIX
NasdaqGS:NBIXBiotechs

Neurocrine’s Two Year CAH Data May Reframe NBIX Valuation Story

Neurocrine Biosciences (NasdaqGS:NBIX) reported new two‑year Phase 3 data from its CAHtalyst Pediatric and Adult trials of CRENESSITY in classic congenital adrenal hyperplasia. The peer‑reviewed results cover both children and adults and highlight durable efficacy alongside physiologic glucocorticoid dosing. Data show sustained reductions in harmful steroid exposure and clinical improvements, including better body mass index and insulin resistance in pediatric patients. These findings...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

BioNTech Faces Tariff Risks And Leadership Shift As Oncology Plans Advance

BioNTech, NasdaqGS:BNTX, faces potential U.S. pharmaceutical tariffs that could affect access to a key market. The company is preparing for the announced departures of its co founders from leadership roles. These developments arrive while the share price stands at $97.54 and recent returns show mixed performance across different time frames. For investors watching NasdaqGS:BNTX, these leadership changes and tariff risks are landing on a share price of $97.54, with recent moves including a...
NasdaqGS:CCC
NasdaqGS:CCCSoftware

CCC Mobile Scanning Links AI Automation With CCC ONE Usage And Valuation

CCC Intelligent Solutions Holdings launched mobile invoice scanning in the CCC ONE platform, integrating directly into its repair management workflow. The new feature uses AI to match invoice line items to repair orders, automating parts reconciliation for repair shops. The capability is available at no additional cost to users of CCC ONE, aiming to cut manual data entry and reduce processing time. CCC Intelligent Solutions Holdings, traded as NasdaqGS:CCC, is rolling out this product...
NYSE:GRMN
NYSE:GRMNConsumer Durables

Garmin’s Record Q1 And EU Wins Raise Questions On Growth Mix

Garmin (NYSE:GRMN) reports record Q1 2026 revenue and operating income, setting new highs for the company. Fitness segment revenue rises 42% in Q1 2026, supported by advanced wearables and recent product launches. Garmin plans around 100 product launches in 2026 across its diversified segments. The company secures multiple new EASA certifications for aviation equipment, expanding its presence in the European market. For investors tracking consumer electronics and aerospace, Garmin sits at...
NYSE:BLX
NYSE:BLXDiversified Financial

Bladex Rebrand Puts NYSE BLX Valuation And Dividend Record In Focus

Banco Latinoamericano de Comercio Exterior S. A. gained shareholder approval at its recent Annual Shareholders' Meeting to change its legal name to Bladex Inc. The rebranding will shift the company’s official identity while it continues to trade on the NYSE under ticker NYSE:BLX. The name change is expected to influence how the bank presents itself to clients, investors, and counterparties across Latin America and beyond. The rebrand to Bladex Inc. comes at a time when NYSE:BLX shares are...
NasdaqGS:NVCR
NasdaqGS:NVCRMedical Equipment

NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook

NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax for locally advanced pancreatic cancer and has started its U.S. commercial launch. The new therapy has seen early adoption and payer coverage in the U.S., expanding NovoCure's reach beyond its original focus in glioblastoma. Pivotal Phase 3 data from the TRIDENT trial in newly diagnosed glioblastoma are expected later this year. NovoCure focuses on tumor treating fields therapy, a medical technology designed to disrupt cancer...
NYSE:MTZ
NYSE:MTZConstruction

MasTec (MTZ) Q1 Earnings Show 2.9% Net Margin That Tests Bullish Expansion Narrative

MasTec (MTZ) opened Q1 2026 with revenue of about US$3.8b and basic EPS of US$0.78, setting the tone for how the rest of the year may shape up on both the top and bottom line. Over the past six reported quarters, revenue has moved from US$3.4b in Q4 2024 to just under US$4.0b in Q3 2025 before landing at US$3.8b in the latest quarter. Quarterly basic EPS has ranged from US$0.13 in Q1 2025 to US$2.07 in Q3 2025 and stands at US$0.78 in Q1 2026. With trailing twelve month net income of...
NYSE:RBRK
NYSE:RBRKSoftware

Does Rubrik (RBRK) Offer Value After Recent Share Price Rebound?

If you are wondering whether Rubrik's current share price reflects its true worth, this breakdown will help you connect the recent moves in the stock to what the underlying valuation signals are saying. Rubrik last closed at US$55.07, with returns of 5.3% over the past week and 13.3% over the past month, while the 1 year return sits at a 24.9% decline. Recent trading interest has been influenced by ongoing attention on data security and cloud software providers, as investors reassess how...
NYSE:AWK
NYSE:AWKWater Utilities

American Water Works Merger News Tests Valuation And Recent Share Weakness

American Water Works Company (NYSE:AWK) has announced a proposed merger with Essential Utilities to create a large regulated U.S. water and wastewater utility. The combined business would bring together regulated water and wastewater operations across multiple states, subject to regulatory and shareholder approvals. The companies plan to integrate networks and services to serve a wider customer base under a unified regulated utility structure. For investors watching NYSE:AWK, this update...
NYSE:EPD
NYSE:EPDOil and Gas

Is It Too Late To Consider Enterprise Products Partners (EPD) After Its Strong Multi‑Year Rally?

If you are asking whether Enterprise Products Partners is still reasonably priced after a long run in the unit price, this article walks through what the current valuation really reflects and where the key pressure points are. The units last closed at US$38.03, with stated returns of 0.1% over 7 days, 1.6% over 30 days, 18.3% year to date, 33.3% over 1 year, 83.1% over 3 years and 134.3% over 5 years, which gives plenty of context for a closer look at value. Recent coverage has focused on...
NYSE:THC
NYSE:THCHealthcare

Is It Time To Reassess Tenet Healthcare (THC) After Its Strong Three Year Share Price Run?

If you are wondering whether Tenet Healthcare at a recent close of US$183.27 still offers value or is looking stretched, the numbers behind the share price can help frame that decision. The stock has returned 1.4% over the last 7 days, while the 30 day and year to date returns of 3.7% decline and 8.1% decline sit alongside a 23.8% return over the last year and 164.3% over 3 years. Recent coverage has focused on Tenet Healthcare's position in the US hospital and healthcare services space,...
NYSE:TSN
NYSE:TSNFood

Is Tyson Foods (TSN) Pricing Look Attractive After Recent Share Price Softness?

If you are wondering whether Tyson Foods at around US$63.68 is a bargain or a value trap, the key is to look past the headline share price and into what the current valuation actually reflects. The stock has slipped about 0.5% over the last week and 1.0% over the last month, but is still showing a 9.7% return year to date and 8.5% over the last year, which can change how investors think about both opportunity and risk. Recent coverage has focused on Tyson Foods as a major player in U.S...
NasdaqGM:KIDS
NasdaqGM:KIDSMedical Equipment

OrthoPediatrics (KIDS) Q1 Losses Challenge Bullish Margin Narratives Despite 11.1% Revenue Growth

OrthoPediatrics (KIDS) opened Q1 2026 with revenue of US$59.4 million and a basic EPS loss of US$0.45, while trailing 12 month figures show revenue of US$243.3 million and a basic EPS loss of US$1.68 as the company continues to operate in the red. Over the past reported periods, revenue has moved from US$52.7 million in Q4 2024 to a range of roughly US$59 million to US$61.6 million through Q1 2026. Quarterly basic EPS has stayed loss making between about US$0.30 and US$0.69 per share. For...
NYSE:FHI
NYSE:FHICapital Markets

Federated Hermes (FHI) Margins At 20.5% Challenge Cautious Earnings Narratives

Federated Hermes (FHI) opened 2026 with Q1 results that put the focus squarely on its income statement, reporting total revenue of US$479 million and basic EPS of US$1.33, underpinned by net income of US$96 million. Over the past six reported quarters, revenue has ranged from US$425 million in Q1 2025 to US$483 million in Q4 2025, while quarterly basic EPS has moved between US$1.04 in Q4 2024 and US$1.39 in Q4 2025. This gives a clear view of how the current print fits into the recent run...
NasdaqGS:QLYS
NasdaqGS:QLYSSoftware

Is It Time To Reconsider Qualys (QLYS) After Its Recent Share Price Slide

If you are wondering whether Qualys is starting to look like value at its current share price, or if the recent moves are a warning sign, this article walks you through what the numbers actually say. The stock last closed at US$88.53, with a 5.0% gain over the past week and a 2.7% move over the last month, set against a 32.4% decline year to date and a 30.8% decline over the past year. These returns sit alongside ongoing interest in cybersecurity providers and recurring revenue models, which...